[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657898":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":38,"studyPopulation":39,"armGroups":40,"interventions":34,"overallOfficials":44,"centralContacts":49,"locations":34,"responsibleParty":55,"collaborators":34,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":34,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":34,"enrollmentInfo":68,"targetDuration":34,"studyType":71,"phases":34,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":82,"whyStopped":34,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":34},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":34},[9],{"measure":10,"description":11,"timeFrame":12},"Change in NYHA functional class","Change in New York Heart Association (NYHA) functional class from baseline to follow-up.","Baseline and at 6 to 12 months",[14,18,21,24,27,31],{"measure":15,"description":16,"timeFrame":17},"Change in KCCQ-12 score","Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) total score from baseline to follow-up (range 0-100, higher scores indicate better health status).","From baseline to 6 to 12 months",{"measure":19,"description":20,"timeFrame":17},"Change in left ventricular ejection fraction","Change in left ventricular ejection fraction (LVEF) measured by echocardiography from baseline to follow-up.",{"measure":22,"description":23,"timeFrame":17},"Change in estimated glomerular filtration rate","Change in estimated glomerular filtration rate (eGFR) calculated by CKD-EPI equation from baseline to follow-up.",{"measure":25,"description":26,"timeFrame":17},"Rate of heart failure hospitalization","Number of heart failure-related hospital admissions during the follow-up period.",{"measure":28,"description":29,"timeFrame":30},"Proportion of patients on each GDMT component","Proportion of patients prescribed each of the four foundational GDMT drug classes at follow-up.","At 6 to 12 months",{"measure":32,"description":33,"timeFrame":30},"Medication adherence score","Mean Morisky Medication Adherence Scale-8 (MMAS-8) score (range 0-8, higher scores indicate better adherence).",null,{"allocation":34,"interventionModel":34,"interventionModelDescription":34,"primaryPurpose":34,"observationalModel":36,"timePerspective":37,"maskingInfo":34},"COHORT","PROSPECTIVE","Guideline-directed medical therapy (GDMT) is the cornerstone of treatment for heart failure with reduced ejection fraction. This observational study will enroll adult patients with chronic HFrEF (LVEF ≤ 40%) who are stable on or planned to initiate GDMT.\n\nPatients will be followed for 6 to 12 months to assess changes in renal function, functional status, quality of life, left ventricular ejection fraction, hospitalization rates, and medication adherence.","Adult patients with chronic heart failure with reduced ejection fraction attending the Cardiovascular Department at Assiut University.",[41],{"label":42,"type":34,"description":43,"interventionNames":34},"Single cohort: HFrEF patients on GDMT","Adult patients with heart failure with reduced ejection fraction who are receiving or planned to receive contemporary guideline-directed medical therapy and will be followed for intermediate outcomes.",[45],{"name":46,"affiliation":47,"role":48},"Ayman k Mohammed, prof","Cardiovascular Medicine Department, Assiut University Hospitals","STUDY_CHAIR",[50],{"name":51,"role":52,"phone":53,"phoneExt":34,"email":54},"Karim A Ali, Resident","CONTACT","+20 10 69625533","kbs621304@gmail.com",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Karim Atef Ali Ahmed","Resident Physician, Department of Cardiovascular medicine","100657898","intermediate-outcomes-of-hfref-patients-on-guideline-directed-medical-therapy-100657898",false,"NCT07845201","Intermediate Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy","Intermediate Outcomes of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) in View of Current Guideline-Directed Medical Therapy","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of chronic HFrEF with LVEF ≤ 40% documented by echocardiography\n* Stable on or planned initiation of guideline-directed medical therapy\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* \\- Acute decompensated heart failure requiring intravenous inotropes at enrollment\n* End-stage renal disease on dialysis\n* eGFR less than 20 mL\u002Fmin\u002F1.73 m² at baseline\n* Severe primary valvular disease requiring immediate intervention\n* Life expectancy less than 6 months due to non-cardiac illness","ALL","18 Years",{"count":69,"type":70},250,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to evaluate intermediate clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical therapy over a 6 to 12 month follow-up period.",[74,75],"Heart Failure With Reduced Ejection Fraction","HFrEF - Heart Failure With Reduced Ejection Fraction",[77,78,79,80,81],"Guideline-directed medical therapy","GDMT","HFrEF","Assiut","Heart failure outcomes","NOT_YET_RECRUITING","2026-09-26",{"date":85,"type":86},"2026-09-30","ACTUAL",{"date":83,"type":70},{"date":89,"type":70},"2028-02-20",{"name":5,"class":6}]